Who Paid My Doc
James Chen
Adult Reconstructive Orthopaedic Surgery Mission Viejo, CA Medical Doctor
NPI 1104210152 CMS profile 4220364
26401 Crown Valley Pkwy Ste 101, Mission Viejo, CA 92691
General payments
$496,730
Research payments
$5,000
Ownership & investment interest
$0
Through program year 2025, James Chen of Mission Viejo, CA is reported in the CMS Open Payments database as having received $496,730 across 626 general payments and $5,000 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 91st percentile of Adult Reconstructive Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $125,186 | 155 | |
| 2024 | General | $136,521 | 155 | |
| 2024 | Research | $500 | 1 | |
| 2023 | General | $174,615 | 215 | |
| 2023 | Research | $4,500 | 12 | |
| 2022 | General | $59,047 | 88 | |
| 2021 | General | $1,362 | 13 |
Beside peers
- James Chen
- Adult Reconstructive Orthopaedic Surgery median
- Middle half of Adult Reconstructive Orthopaedic Surgery
- National median
In program year 2025, general payments to James Chen were reported at $125,186. Among 1,079 Adult Reconstructive Orthopaedic Surgery profiles paid that year, the median was $1,406 and the middle half received between $318 and $8,709.
Show as a table
| Year | James Chen | Adult Reconstructive Orthopaedic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $1,416 | $292–$9,336 | $163 |
| 2020 | $0 | $647 | $141–$6,474 | $114 |
| 2021 | $1,362 | $1,073 | $211–$6,497 | $132 |
| 2022 | $59,047 | $1,217 | $236–$6,299 | $149 |
| 2023 | $174,615 | $1,082 | $246–$6,818 | $160 |
| 2024 | $136,521 | $1,575 | $323–$8,944 | $164 |
| 2025 | $125,186 | $1,406 | $318–$8,709 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 11 drugsPart D claims
748
Drug cost
$21,690
Branded share of claims
7.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 36 | $18,402 | |
| Oxycodone Hcl | Generic | 100 | $809 | |
| Meloxicam | Generic | 247 | $584 | |
| Celecoxib | Generic | 20 | $580 | |
| Cefadroxil | Generic | 57 | $287 | |
| Tramadol Hcl | Generic | 81 | $260 | |
| Methocarbamol | Generic | 57 | $228 | |
| Cephalexin | Generic | 15 | $194 | |
| Gabapentin | Generic | 34 | $138 | |
| Amoxicillin | Generic | 81 | $123 |
The 10 drugs with the highest cost, of 11 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 115 billing codesPaid by Medicare
$428,585
Medicare patients
633
Services billed
7,650
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 69% | |
| Ischemic heart disease | 25% | |
| Depression | 25% | |
| Osteoporosis | 24% | |
| Diabetes | 19% | |
| Chronic kidney disease | 19% | |
| Atrial fibrillation | 18% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg J7329 | Office | 30 | 3,150 | $17,318 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 160 | 1,101 | $850 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
639 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Adult Reconstructive Orthopaedic Surgery in California
William Maloney
Adult Reconstructive Orthopaedic Surgery · Stanford, CA
James Caillouette
Adult Reconstructive Orthopaedic Surgery · Newport Beach, CA
William Long
Adult Reconstructive Orthopaedic Surgery · Los Angeles, CA
John Dearborn
Adult Reconstructive Orthopaedic Surgery · Menlo Park, CA
William Bugbee
Adult Reconstructive Orthopaedic Surgery · La Jolla, CA
James Huddleston
Adult Reconstructive Orthopaedic Surgery · Stanford, CA
Related records
Adult Reconstructive Orthopaedic Surgery in California
Practitioners in the same specialty and state, ranked by reported value.
All Adult Reconstructive Orthopaedic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.